Evidence map›Paper›PMID 30276649›Full record

ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2019

Pre-eclampsia: the role of highly active antiretroviral therapy and immune markers.

Wendy N Phoswa, Thajasvarie Naicker, Veron Ramsuran, Jagidesa Moodley

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Anti-hypertensive use for non-severe gestational hypertension in Botswana: A case-control study.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2022
    Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Review
  12. Review
  13. Is pregnancy a risk factor of COVID-19?European journal of obstetrics, gynecology, and reproductive biology · 2020
    Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Wendy N PhoswaDiscipline of Obstetrics and Gynaecology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. phoswawendy@gmail.com.ORCID http://orcid.org/0000-0002-7769-4528
Thajasvarie NaickerOptics and Imaging Centre, University of KwaZulu-Natal, Durban, South Africa.
Veron RamsuranKwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
Jagidesa MoodleyWomen's Health and HIV Research Group, University of KwaZulu-Natal, Durban, South Africa.
University of KwaZulu-Natal · ZACentre for the AIDS Programme of Research in South Africa · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of the reviewThis review highlights the role immune cells and markers such as natural killer (NK) cells, cytokines and human leukocyte antigen (HLA-G) play in predisposing HIV-infected women who are on HAART to develop PE, thus contributing to a better understanding and early diagnosis of PE with a subsequent reduction in maternal foetal and neonatal deaths. RECENT

findingsPregnant women infected with the Human Immunodeficiency Virus (HIV) have a 25% risk of mother to child transmission. This risk, however, decreases to 2% if the women is on treatment. Highly active antiretroviral therapy (HAART) is the recommended treatment for both pregnant and non-pregnant women infected with HIV. Treatment with HAART is reported to potentiate predisposition to the development of hypertensive disorders of pregnancy such as pre-eclampsia (PE). Pre-eclampsia accounts for 7-10% of abnormal pregnancies worldwide. Studies demonstrate that pregnant women with HIV have PE at lower frequencies than uninfected women, however, the converse is observed upon HAART initiation. HIV-infected women on HAART exhibit a greater tendency to develop PE, emanating from immune reconstitution induced by HAART. There is paucity of information as to the pathogenesis of PE upon HAART initiation and there are, therefore, controversial data as to whether HAART predisposes women to a lower, equal or higher risk of PE development compared to the general population, further investigations on the impact of HIV infection and HAART on the immune response and rate of PE development in HIV infected pregnant women are urgently needed.

Indexed as

Antiretroviral Therapy, Highly ActiveAnimalsBiomarkersCytokinesFemaleHIV InfectionsHLA-G AntigensHumansKiller Cells, NaturalPre-EclampsiaPregnancyPregnancy Complications, InfectiousBiomarkersCytokinesHLA-G AntigensHighly active antiretroviral therapyHuman immunodeficiency virusImmune markersPre-eclampsiaPregnancy

Identifiers

PMID30276649
OpenAlexW2895485272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.